MTMahnaz Talebi

Mahnaz Talebi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mahnaz Talebi has a total of 201 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Management of Urinary Symptoms in Multiple Sclerosis: An Umbrella Review

    by Sina Hamzehzadeh, Donyasadat Hashemian, Saman Baharomid, Fateme Tahmasebi, Seyedemad Seyedgholami Sharabiani, Sakineh Hajebrahimi, Mahnaz Talebi, Hanieh Salehi‐Pourmehr, Amirreza Naseri

    Background: Lower urinary tract dysfunctions (LUTDs) are prevalent among patients with multiple sclerosis (MS), which is the most common immune‐mediated neurologic disease among the juvenile population. This study aims to evaluate the efficacy and safety of different methods in the management of MS‐related LUTD. Methods: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and Joanna Briggs Institute (JBI) methods. Systematic review studies that reported the efficacy of any management method for LUTD in MS are considered for inclusion. A systematic search was conducted in PubMed, Scopus, Embase, and Web of Science and risk of bias was assessed using the JBI critical appraisal checklist for systematic reviews. Results: Out of 342 screened records, 34 systematic reviews were included. Preliminary efficacy and safety of pelvic floor muscle training (PFMT) and tibial nerve stimulation (TNS), as well as the potential of alpha‐blockers, cannabinoids, mirabegron, spinal cord stimulation, sacral neuromodulation, transcranial neuromodulations, vaginal/rectal and clitoral/penile stimulation, foot reflexology, craniosacral therapy, and stem cell therapy were suggested. Despite the appropriate efficacy, anticholinergics, desmopressin, intradetrusor injections of botulinum toxin A, vanilloids, and catheterization were found to cause considerable side effects. Discussion: Despite a high prevalence of LUTDs in MS patients, evidence basis of the management methods is still poor and there is lack of well‐designed randomized controlled trials, which makes evidence inconclusive. Future research is needed to refine treatment algorithms, investigate the potential of combination therapies, and develop individualized treatment paradigms.

  • Leukotriene inhibitors in multiple sclerosis: a systematic review of animal studies

    by Sina Pakkhesal, Shideh Roshani, Ali Mehdizadeh Kahnamoyi, Mahsa Aminzadeh, Sina Ghasemi, Farinaz Amirikar, Mahnaz Talebi, Sarvin Sanaie, Amirreza Naseri

  • Fatigue and contributing factors in relapsing-remitting multiple sclerosis: a descriptive study based on the comprehensive fatigue assessment battery for multiple sclerosis (CFAB-MS)

    by Sina Naghilou, Seyedeh Farinaz Fattahpour, Shahriar Parvaneh, Sarvin Sanaie, Reza Mosaddeghi-Heris, Malihe Talebi, Mahnaz Talebi, Amirreza Naseri

    Introduction Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. The Comprehensive Fatigue Assessment Battery for Multiple Sclerosis (CFAB-MS) is a questionnaire designed to assess fatigue and its contributing factors, including sleep, pain, mobility, stress, anxiety, mood, and fatigue management skills. Methods In this cross-sectional descriptive study, patients with a definitive diagnosis of relapsing-remitting MS (RRMS) and Expanded Disability Status Scale (EDSS) < 4, based on the MacDonald 2017 criteria, were included. Patients with diagnosed depression, other neurological disorders, or progressive forms of MS were excluded. CFAB-MS was used to evaluate fatigue and its related factors. SPSS software version 23 and PRISM 9 were used for statistical evaluations. Results A total of 123 patients with RRMS participated in this study. The average age was 34.12 ± 8.61. Of the total number of patients, 92 (74.8%) were women and 31 (25.2%) were men. The most common issues in the study population were anxiety and worry, fatigue, and stress. EDSS was correlated with fatigue (correlation r: 0.331; p-value < 0.001), pain (correlation r: 0.187; p-value: 0.040), stress (correlation r: 0.186; p-value: 0.041), anxiety (correlation r: 0.206; p-value: 0.023), and walking disability (correlation r: 0.376; p-value < 0.001) VAS. Physical, Psychological, and Social Fatigue Index was correlated to all results obtained with the VAS (p-values < 0.05). Conclusion Factors such as age, EDSS, pain, sleep problems, stress, mood, anxiety and worry, nutrition, mobility, and environment are associated with fatigue in RRMS patients with EDSS < 4, which should be considered by clinicians to achieve appropriate management of fatigue in this population.


  • Open Access

    Sensitivity and specificity of the CANTAB Paired Associates Learning test for identifying mild cognitive impairment

    by Yashar Nabizadeh, Malihe Talebi, Elnaz Gholipour-Khalili, Hamidreza Ashayeri, Mahnaz Talebi, Amirreza Naseri


  • Open Access

    The Association Between Serum α‐Tocopherol and Pathogenesis of Multiple Sclerosis: A Systematic Review and Meta‐Analysis of Case‐Control Studies

    by Hamid Abbasi, Behnaz Ahmadi, Navid Sherafati, Reza Ansarian, Seyedyashar Pourebrahimian Leilabadi, Sina Hamzehzadeh, Reyhane Dehzadeh, Mahnaz Talebi, Sarvin Sanaie, Leila Nikniaz, et al.

    Oxidative stress is a key pathological mechanism of multiple sclerosis (MS) and α‐tocopherol is recognized as a primary chain‐breaking antioxidant. This study is aimed at investigating the relationship between serum α‐tocopherol and the pathogenesis of MS This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and the Joanna Briggs Institute (JBI) manual for evidence synthesis. Scopus, PubMed, Web of Science, and Embase were searched in March 2025. The risk of bias was evaluated using the critical appraisal tool developed by JBI. All statistical analyses were performed with comprehensive meta‐analysis software (CMA3). Out of 506 records evaluated during the title/abstract screening phase, five case‐control studies were included. Studies encompassed a total of 389 participants, comprising 211 individuals diagnosed with MS and 178 healthy controls. The levels of α‐tocopherol were found to be lower in MS patients compared to the healthy group (standardized mean difference [SMD] = −1.17; 95% CI: −2.02, −0.31; p = 0.007, I 2 = 91.5%, p < 0.001; predictive values: −3.13, 0.79). Although subgroup analyses were performed based on sample size, sex, and phase of the diseases, the source of heterogeneity was not found. Current evidence supports the possible association of serum α‐tocopherol and MS pathogenesis; however, considering the restricted number of included studies (five papers), the retrospective nature of the studies, and substantial heterogeneity in the conducted quantitative synthesis, multicenter and large‐scale prospective studies are recommended.

  • Open Access

    Dietary regimens and cognitive function in multiple sclerosis: a systematic review

    by Hila Navadeh Shahla, Farid Jahanshahlou, Mehrdad Nourizadeh, Bita Ostad-Hassanzadeh, Shideh Roshani, Mahnaz Talebi, Sarvin Sanaie, Amirreza Naseri

  • Open Access

    The association between depressive symptoms and sleep quality in patients with multiple sclerosis: a systematic review and meta-analysis

    by Afshin Moradi, Asal Ebrahimian, Mahnaz Talebi, Amirreza Naseri

    Multiple sclerosis (MS) is a chronic, immune-mediated disease often associated with neuropsychiatric complications, including depressive symptoms and sleep disturbances. Evidence regarding their association remains inconsistent; therefore, this systematic review and meta-analysis aimed to investigate the correlation between depressive symptoms and sleep quality in patients with MS. A systematic search was conducted across PubMed, Embase, Web of Science, and Scopus up to February 2, 2025. Cross-sectional and case-control studies which assessed sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and depressive symptoms using validated instruments were included. Two independent reviewers conducted the study selection, data extraction, and risk of bias assessment. Pooled correlation coefficients (r) were calculated using Comprehensive Meta-Analysis software (CMA). Twenty-one studies comprising 3,144 patients with MS were included. Depressive symptoms were assessed using the scales including Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS), Hamilton Depression Rating Scale (HDRS). Meta-analysis demonstrated a moderate positive correlation between PSQI and different scales of depressive symptoms (r = 0.46, 95% CI: 0.37-0.55, p < 0.01); however, heterogeneity was considerable (I² = 83.3%). The certainty of evidence was low considering the observational nature of the included studies and substantial inconsistency. Subgroup analysis of studies based on the scales of depressive symptoms showed lower heterogeneity. This review suggests a possible association between poor sleep quality and depressive symptoms in patients with MS; however, the findings should be interpreted cautiously because of the low certainty of evidence. Further well-designed prospective studies are needed to clarify the strength and direction of this relationship.


  • Open Access

    An Exploratory Cross-Sectional Study of the Association Between Regular Cigarette Smoking and Level of Disability, Hand Dexterity, Cognitive Impairment, Fatigue, and Markers of Oxidative Stress in Male Patients With Relapsing-Remitting Multiple Sclerosis

    by Melika Ahmadi Bonabi, Reza Mosaddeghi-Heris, Niloofar Taheri, Mahnaz Talebi, Amirreza Naseri

    Cigarette smoking is a recognized risk factor for multiple sclerosis (MS) development and progression; however, the association between smoking and features of MS in male patients remains insufficiently explored. A cross-sectional exploratory study was conducted involving 31 male patients with approved relapsing–remitting MS (RRMS), divided into smokers ( n = 9) and non-smokers ( n = 22). The Symbol Digit Modalities Test (SDMT) and Paced Auditory Serial Addition Test (PASAT) were used to assess cognitive performance. Hand dexterity was evaluated using the 9-Hole Peg Test (9HPT). Depressive symptoms and disability were assessed via the Beck Depression Inventory (BDI) and the Expanded Disability Status Scale (EDSS), respectively. Fatigue and related factors were assessed using the Comprehensive Fatigue Assessment Battery for Multiple Sclerosis (CFAB-MS). Serum markers of oxidative stress and antioxidant status, including superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), total antioxidant capacity (TAC), malondialdehyde (MDA), and glutathione (GSH), were also measured. Smokers demonstrated significantly lower SDMT scores compared with non-smokers (36.86 ± 11.16 vs. 52.47 ± 18.54; p = .04), which was no longer significant after adjusting for EDSS and age. No significant differences were observed between groups in PASAT, 9HPT, EDSS, or BDI. Smokers reported higher anxiety and worry scores on the CFAB-MS ( p < .05), while other fatigue-related domains were comparable between groups. Regarding the oxidative stress markers, a statistically significant difference was only detected in SOD activity. Regular cigarette smoking may be associated with decreased cognitive processing speed and increased anxiety in male patients with RRMS, which warrants further investigation.


  • Open Access

    The correlation between serum markers of oxidative stress and fatigue and related factors in minimally disabled patients with relapsing-remitting multiple sclerosis

    by Ali Alipour, Reza Mosaddeghi-Heris, Afra Darvishi, Shahriar Parvaneh, Malihe Talebi, Niloofar Taheri, Mahnaz Talebi, Amirreza Naseri

    Oxidative stress is recognized as a key pathological mechanism in multiple sclerosis (MS), and fatigue is one of the most prevalent and disabling symptoms. In this cross-sectional study, 85 patients diagnosed with relapsing-remitting MS (RRMS) and Expanded Disability Status Scale (EDSS) < 4.5 were recruited. Fatigue was evaluated by the Comprehensive Fatigue Assessment battery MS (CFAB-MS), which also assesses fatigue-related factors. Venous blood samples were collected to measure levels of glutathione peroxidase (GPX), catalase (CAT), malondialdehyde (MDA), reduced glutathione (GSH), total antioxidant capacity (TAC), and superoxide dismutase (SOD). Most correlations between oxidative stress markers and fatigue measures were not statistically significant. However, MDA levels showed significant positive correlations with Visual Analog Scale (VAS) scores for sleep problems (r:0.23, p-value:0.04); Walking problems VAS (r:0.31, p-value < 0.01); anxiety and worry (r:0.22, p-value < 0.05); and significant negative correlations with mood (r:-0.21, p-value < 0.05) and fatigue management (r:-0.22, p-value:0.04). Additionally, GSH levels were positively correlated with Fatigue VAS (r:0.24, p-value:0.02) and CAT was negatively correlated with stress VAS (r:-0.21, p-value:0.04). After applying the Benjamini-Hochberg correction, none of the correlations remained statistically significant. At an exploratory level, this study suggests that there is a minimal association between oxidative stress, fatigue and its related factors in minimally disabled RRMS patients.


  • The effects of probiotics supplementation on serum markers of oxidative stress in relapsing-remitting multiple sclerosis: a randomised, double-blind, placebo-controlled clinical trial

    by N. Mohy, S. Sanaie, S. Rahnemayan, M. Yousefi, M. Talebi, A. Naseri

    Oxidative stress is a significant contributor to neuronal damage in multiple sclerosis (MS), marked by an imbalance in reactive oxygen species and antioxidant defences. Probiotics may modulate oxidative stress and improve antioxidant levels. This double-blind, randomised, placebo-controlled clinical trial aimed to evaluate the effects of probiotics supplementation on serum oxidative stress markers and endogenous antioxidants in patients with relapsing-remitting MS (RRMS). Ninety RRMS patients with expanded disability status scale [EDSS] < 4 were randomised into two groups: a probiotics group (Lactocare®) and a placebo group, and received the interventions twice daily for four months. Serum levels of oxidative stress markers (malondialdehyde [MDA]), endogenous antioxidants (glutathione peroxidase [GPx] activity, superoxide dismutase [SOD], catalase activity [CAT], glutathione [GSH]), and total antioxidant capacity (TAC) were measured at baseline and post-treatment. Fifty-five patients, including 26 patients in the probiotic group and 29 patients in the placebo group, completed the study. Both groups showed significant within-group improvements in GPx activity, SOD, and GSH levels, as well as reductions in MDA levels ( ); however, no significant between-group differences were found for any markers ( ). TAC and CAT levels remained unchanged in both groups. Findings of this study did not support the evidence for antioxidant effects of probiotics supplementation in RRMS patients, and its effects on oxidative stress markers in RRMS patients are found to be comparable to placebo. Iranian Registry of Clinical Trials: IRCT20220713055465N2, registration date: 2023.5.9